Compugen signs cancer drug licensing deal with Gilead Sciences
US biopharmaceutical giant Gilead Sciences Inc. (Nasdaq: GILD) today announced an agreement with Israeli clinical-stage cancer immunotherapy company Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), which uses computational…
